S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94

AbbVie News Headlines

$109.33
+0.42 (+0.39 %)
(As of 10/15/2021 04:00 PM ET)
Add
Compare
Today's Range
$109.08
$109.96
50-Day Range
$106.40
$120.78
52-Week Range
$79.11
$121.53
Volume4.63 million shs
Average Volume7.00 million shs
Market Capitalization$193.21 billion
P/E Ratio29.47
Dividend Yield4.77%
Beta0.82

Media Mentions By Week

AbbVie Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ABBV
News Sentiment

0.24

0.31

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ABBV Articles
This Week

18

18

ABBV Articles
Average Week

Get AbbVie News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.

AbbVie (NYSE ABBV) News Headlines Today

SourceHeadline
marketbeat.com logoAbbVie Forms Flat Base Ahead Of Q3 Earnings Report
marketbeat.com - October 13 at 6:10 AM
seekingalpha.com logoAbbVie: The Humira Situation Remains Scary
seekingalpha.com - October 15 at 3:16 PM
seekingalpha.com logoAbbVie: The Humira Situation Remains Scary - Seeking Alpha
seekingalpha.com - October 15 at 2:57 PM
finance.yahoo.com logoAbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU)
finance.yahoo.com - October 15 at 9:56 AM
seekingalpha.com logoAbbVie Inc.: Dissect Its Growth Sustainability And Capital Allocation Like Buffett - Seeking Alpha
seekingalpha.com - October 12 at 1:01 PM
finance.yahoo.com logoAllergan Aesthetics Launches Series of Initiatives to Support Breast Cancer Awareness
finance.yahoo.com - October 11 at 9:11 AM
seekingalpha.com logoEli Lilly, AbbVie favorites at JP Morgan as big pharma set for Q3 earnings (NYSE:MRK) - Seeking Alpha
seekingalpha.com - October 9 at 11:33 PM
nasdaq.com logoIs It Worth Considering AbbVie Inc. (NYSE:ABBV) For Its Upcoming Dividend? - Nasdaq
nasdaq.com - October 9 at 1:32 PM
seekingalpha.com logoAbbVie Vs. Moderna Stock: Which Is The Better Buy?
seekingalpha.com - October 8 at 7:47 AM
fool.com logoWhy AbbVie Stock Sank in September - Motley Fool
fool.com - October 7 at 1:37 PM
finance.yahoo.com logoWhy AbbVie Stock Sank in September
finance.yahoo.com - October 7 at 1:37 PM
finance.yahoo.com logoHealth Canada Approves the Use of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Moderate to Severe Atopic Dermatitis
finance.yahoo.com - October 7 at 1:37 PM
finance.yahoo.com logoAbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis - Yahoo Finance
finance.yahoo.com - October 7 at 8:36 AM
finance.yahoo.com logoAbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis
finance.yahoo.com - October 7 at 8:36 AM
finance.yahoo.com logoAbbVie's Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis
finance.yahoo.com - October 7 at 8:36 AM
finance.yahoo.com logoAbbVie Stock Is Making A Comeback On Inflammatory Drugs — Is It A Buy Now?
finance.yahoo.com - October 6 at 5:37 PM
finance.yahoo.com logoAbbVie to Host Third-Quarter 2021 Earnings Conference Call
finance.yahoo.com - October 5 at 8:53 AM
seekingalpha.com logoAbbVie Appears Ready To Reverse And Outperform
seekingalpha.com - October 5 at 6:30 AM
nasdaq.com logoAbbVie (ABBV) Stock Moves -0.33%: What You Should Know - Nasdaq
nasdaq.com - October 4 at 10:51 PM
finance.yahoo.com logoAbbVie (ABBV) Stock Moves -0.33%: What You Should Know
finance.yahoo.com - October 4 at 10:51 PM
seekingalpha.com logoIs AbbVie A Good Dividend Stock? Perceived Risks Offer Tremendous Value - Seeking Alpha
seekingalpha.com - October 4 at 5:50 PM
finance.yahoo.com logoBotox war: East Bay challenger sued by maker of blockbuster cosmetic toxin
finance.yahoo.com - October 4 at 5:50 PM
benzinga.com logoAbbVie Presents New Upadacitinib Data In Atopic Dermatitis - Benzinga
benzinga.com - September 30 at 9:25 PM
seekingalpha.com logoAbbvie data shows Skyrizi efficacy in psoriatric arthritis maintained for a year - Seeking Alpha
seekingalpha.com - September 30 at 4:25 PM
finance.yahoo.com logoAbbVie Presents New Analyses Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis Across Patient Characteristics and Body Regions at EADV Virtual Congress - Yahoo Finance
finance.yahoo.com - September 30 at 11:24 AM
finance.yahoo.com logoAbbVie Presents Late-Breaking Data on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at the 30th European Academy of Dermatology and Venereology (EADV) Congress - Yahoo Finance
finance.yahoo.com - September 30 at 11:24 AM
finance.yahoo.com logoAbbVie Presents New Analyses Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis Across Patient Characteristics and Body Regions at EADV Virtual Congress
finance.yahoo.com - September 30 at 11:24 AM
finance.yahoo.com logoAbbVie Presents Late-Breaking Data on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at the 30th European Academy of Dermatology and Venereology (EADV) Congress
finance.yahoo.com - September 30 at 11:24 AM
reuters.com logoU.S. FDA approves AbbVie's migraine prevention drug - Reuters
reuters.com - September 29 at 8:23 PM
finance.yahoo.com logoThe Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug - Yahoo Finance
finance.yahoo.com - September 29 at 3:22 PM
finance.yahoo.com logoAbbVie's (ABBV) Migraine Prevention Drug Qulipta Gets FDA Nod
finance.yahoo.com - September 29 at 3:22 PM
fool.com logoHere's Why AbbVie Is a Great Healthcare Stock for Long-Term Investors - Motley Fool
fool.com - September 29 at 9:53 AM
fool.com logoHere's Why AbbVie Is a Great Healthcare Stock for Long-Term Investors
fool.com - September 29 at 8:59 AM
fool.com logoCould AbbVie's New Collaboration Be a Blockbuster? - The Motley Fool
fool.com - September 29 at 2:37 AM
finance.yahoo.com logoUPDATE 1-U.S. FDA approves AbbVie's migraine prevention drug
finance.yahoo.com - September 29 at 2:37 AM
seekingalpha.com logoRegenxbio: Unlocking Value Through The Mega AbbVie Partnership
seekingalpha.com - September 27 at 7:47 PM
seekingalpha.com logoAbbVie Is A Cheap Large Cap With New Drugs To Come - Seeking Alpha
seekingalpha.com - September 27 at 5:39 PM
seekingalpha.com logoAbbVie: When The Going Gets Tough - Seeking Alpha
seekingalpha.com - September 27 at 12:39 PM
finance.yahoo.com logoAmericans are Frustrated by Unexpected Blurry Near Vision Issues, a New Survey Reveals
finance.yahoo.com - September 27 at 12:39 PM
nasdaq.com logoCould AbbVie's New Collaboration Be a Blockbuster? - Nasdaq
nasdaq.com - September 27 at 7:35 AM
seekingalpha.com logoAbbVie unveils valuation discount after selloff amid mixed views on its prospects - Seeking Alpha
seekingalpha.com - September 25 at 11:32 PM
seekingalpha.com logoAbbVie unveils valuation discount after selloff amid mixed views on its prospects
seekingalpha.com - September 25 at 9:53 PM
seekingalpha.com logoWelcoming New Positions In AbbVie And VICI Properties - Seeking Alpha
seekingalpha.com - September 24 at 9:43 AM
seekingalpha.com logoWelcoming New Positions In AbbVie And VICI Properties
seekingalpha.com - September 24 at 4:46 AM
seekingalpha.com logo4.9% Yielding AbbVie Is The Best Buffett Aristocrat Bargain You Can Buy
seekingalpha.com - September 24 at 2:12 AM
seekingalpha.com logo4.9% Yielding AbbVie Is The Best Buffett Aristocrat Bargain You Can Buy - Seeking Alpha
seekingalpha.com - September 24 at 12:17 AM
nasdaq.com logoNovember 5th Options Now Available For AbbVie - Nasdaq
nasdaq.com - September 23 at 1:58 PM
finance.yahoo.com logoAbbVie Presents New Data Analyses for Growing Dermatology Portfolio at the 30th European Academy of Dermatology and Venereology (EADV) Congress - Yahoo Finance
finance.yahoo.com - September 23 at 1:58 PM
fool.com logo3 Relatively Safe Pharma Stocks You Can Buy Right Now - Motley Fool
fool.com - September 23 at 8:57 AM
finance.yahoo.com logo3 Relatively Safe Pharma Stocks You Can Buy Right Now
finance.yahoo.com - September 23 at 8:57 AM
finance.yahoo.com logoAbbVie Presents New Data Analyses for Growing Dermatology Portfolio at the 30th European Academy of Dermatology and Venereology (EADV) Congress
finance.yahoo.com - September 23 at 8:57 AM
Get AbbVie News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 10/16/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.